These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25834026)

  • 21. Off-label prescribing in macular degeneration.
    McCartney M
    BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651
    [No Abstract]   [Full Text] [Related]  

  • 22. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 23. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
    Lotery A; MacEwen C
    BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perhaps the Avastin debate should be resolved in court.
    Fell G
    BMJ; 2015 Apr; 350():h2044. PubMed ID: 25901019
    [No Abstract]   [Full Text] [Related]  

  • 26. The GMC's stance on Avastin.
    Dickson N
    BMJ; 2015 Apr; 350():h2043. PubMed ID: 25898987
    [No Abstract]   [Full Text] [Related]  

  • 27. Minister rules out use of Avastin over Lucentis for wet AMD.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 29. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.
    Harris MJ
    BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986
    [No Abstract]   [Full Text] [Related]  

  • 30. Doctors warn against using Avastin for macular degeneration.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2483. PubMed ID: 20453011
    [No Abstract]   [Full Text] [Related]  

  • 31. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.
    Kaiser PK; Cruess AF; Bogaert P; Khunti K; Kelly SP
    Graefes Arch Clin Exp Ophthalmol; 2012 Nov; 250(11):1563-71. PubMed ID: 23011000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden].
    Bro T
    Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unlicensed medicines: the right to prescribe 'specials' and the problem of overcharging.
    Griffith R
    Br J Community Nurs; 2013 Aug; 18(8):380-2. PubMed ID: 24225472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.
    Wickremasinghe S; Abedi F; Sandhu SS; Guymer R
    Clin Exp Ophthalmol; 2013 Nov; 41(8):723-6. PubMed ID: 24152187
    [No Abstract]   [Full Text] [Related]  

  • 36. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
    Janzen RW; Ludwig WD;
    Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US ophthalmologists plead with drug regulator not to restrict access to Avastin.
    Cohen D
    BMJ; 2015 Mar; 350():h1266. PubMed ID: 25744537
    [No Abstract]   [Full Text] [Related]  

  • 39. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.
    Cohen D
    BMJ; 2015 Apr; 350():h1981. PubMed ID: 25869865
    [No Abstract]   [Full Text] [Related]  

  • 40. A poke in the eye.
    Gurney M
    Nurs Older People; 2007 Dec; 19(10):3. PubMed ID: 18220056
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.